Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


GB virus C (hepatitis G) infection

INTRODUCTION

Two viral agents related to hepatitis have been isolated and designated hepatitis G virus (HGV) and GB virus type C (GBV-C). Molecular characterization of these flaviviruses has shown them to be virtually identical isolates of the same virus [1,2]. In comparison, HGV has only 29 percent amino acid homology with HCV [3].

HGV was initially cloned from a surgeon (whose initials were GB, hence the term GB virus or GBV). Plasma from this patient transmitted hepatitis to tamarins. Three different GBV agents were isolated and designed GB virus types A, B, and C; the first two were probably tamarin agents [3]. The agent designated GBV-C is virtually identical to HGV and can be spread by transfusion of contaminated blood and sexual contact, similar to hepatitis C virus and hepatitis B virus [2,4].

DISTRIBUTION

GBV-C has a global distribution, with a high prevalence in the United States donor population. Currently, GBV-C can be diagnosed only by detecting its RNA in the serum by polymerase chain reaction. However, the sensitivity and specificity of this test are not known [3], and one study suggests that it may significantly underestimate the true incidence of infection [5]. In this report, serial serum samples were obtained from 116 injection drug users over a 6.5 year period; a marker of GBV-C infection (either RNA or antibody) was detected in 110, 70 of whom had anti-GBV-C antibodies but were never positive for GBV-C RNA. All eight patients who cleared GBV-C RNA were antibody positive and there were no new infections in 61 antibody-positive subjects. Thus, anti-GBV-C antibodies appear to be highly associated with viral clearance and protection from reinfection.

CLINICAL SIGNIFICANCE OF GBV-C INFECTION

The clinical significance of GBV-C infection with respect to acute or chronic hepatitis is not well understood, but the preponderance of other evidence suggests that GBV-C does not cause hepatitis in humans [6,7].

GBV-C RNA has been detected in patients with acute non-A to non-E viral hepatitis, in patients with chronic hepatitis of presumed viral etiology, in patients with cryptogenic cirrhosis, and in some patients with primary hepatocellular carcinoma. However, it is often difficult to tease out the direct role of GBV-C in these settings since coinfection with HCV is so common. Studies in patients with apparently isolated GBV-C infection suggest that the acute liver injury is similar to and may be less severe than that with HCV [3]. On the other hand, in patients with post-transfusion hepatitis in whom the presence of GBV-C can be documented, the plasma ALT peak and the peak viral titers may be discordant, suggesting that GBV-C may not be responsible for the elevation in ALT levels.

    

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Aug 2014. | This topic last updated: Apr 3, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Linnen J, Wages J Jr, Zhang-Keck ZY, et al. Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 1996; 271:505.
  2. Alter HJ. The cloning and clinical implications of HGV and HGBV-C. N Engl J Med 1996; 334:1536.
  3. Di Bisceglie AM. Hepatitis G virus infection: a work in progress. Ann Intern Med 1996; 125:772.
  4. Frey SE, Homan SM, Sokol-Anderson M, et al. Evidence for probable sexual transmission of the hepatitis g virus. Clin Infect Dis 2002; 34:1033.
  5. Thomas DL, Vlahov D, Alter HJ, et al. Association of antibody to GB virus C (hepatitis G virus) with viral clearance and protection from reinfection. J Infect Dis 1998; 177:539.
  6. Theodore D, Lemon SM. GB virus C, hepatitis G virus, or human orphan flavivirus? Hepatology 1997; 25:1285.
  7. Feucht HH, Zöllner B, Polywka S, et al. Distribution of hepatitis G viremia and antibody response to recombinant proteins with special regard to risk factors in 709 patients. Hepatology 1997; 26:491.
  8. Tanaka E, Alter HJ, Nakatsuji Y, et al. Effect of hepatitis G virus infection on chronic hepatitis C. Ann Intern Med 1996; 125:740.
  9. Bralet MP, Roudot-Thoraval F, Pawlotsky JM, et al. Histopathologic impact of GB virus C infection on chronic hepatitis C. Gastroenterology 1997; 112:188.
  10. Jarvis LM, Davidson F, Hanley JP, et al. Infection with hepatitis G virus among recipients of plasma products. Lancet 1996; 348:1352.
  11. Fried MW, Khudyakov YE, Smallwood GA, et al. Hepatitis G virus co-infection in liver transplantation recipients with chronic hepatitis C and nonviral chronic liver disease. Hepatology 1997; 25:1271.
  12. Vargas HE, Laskus T, Radkowski M, et al. Hepatitis G virus coinfection in hepatitis C virus-infected liver transplant recipients. Transplantation 1997; 64:786.
  13. Pessoa MG, Terrault NA, Detmer J, et al. Quantitation of hepatitis G and C viruses in the liver: evidence that hepatitis G virus is not hepatotropic. Hepatology 1998; 27:877.
  14. Yoshiba M, Okamoto H, Mishiro S. Detection of the GBV-C hepatitis virus genome in serum from patients with fulminant hepatitis of unknown aetiology. Lancet 1995; 346:1131.
  15. Kanda T, Yokosuka O, Ehata T, et al. Detection of GBV-C RNA in patients with non-A-E fulminant hepatitis by reverse-transcription polymerase chain reaction. Hepatology 1997; 25:1261.
  16. Muñoz SJ, Alter HJ, Nakatsuji Y, et al. The significance of hepatitis G virus in serum of patients with sporadic fulminant and subfulminant hepatitis of unknown etiology. Blood 1999; 94:1460.
  17. Yeo AE, Matsumoto A, Hisada M, et al. Effect of hepatitis G virus infection on progression of HIV infection in patients with hemophilia. Multicenter Hemophilia Cohort Study. Ann Intern Med 2000; 132:959.
  18. Lefrère JJ, Roudot-Thoraval F, Morand-Joubert L, et al. Carriage of GB virus C/hepatitis G virus RNA is associated with a slower immunologic, virologic, and clinical progression of human immunodeficiency virus disease in coinfected persons. J Infect Dis 1999; 179:783.
  19. Xiang J, Wünschmann S, Diekema DJ, et al. Effect of coinfection with GB virus C on survival among patients with HIV infection. N Engl J Med 2001; 345:707.
  20. Tillmann HL, Heiken H, Knapik-Botor A, et al. Infection with GB virus C and reduced mortality among HIV-infected patients. N Engl J Med 2001; 345:715.
  21. Berzsenyi MD, Bowden DS, Kelly HA, et al. Reduction in hepatitis C-related liver disease associated with GB virus C in human immunodeficiency virus coinfection. Gastroenterology 2007; 133:1821.
  22. Nunnari G, Nigro L, Palermo F, et al. Slower progression of HIV-1 infection in persons with GB virus C co-infection correlates with an intact T-helper 1 cytokine profile. Ann Intern Med 2003; 139:26.
  23. Xiang J, George SL, Wünschmann S, et al. Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1. Lancet 2004; 363:2040.
  24. Williams CF, Klinzman D, Yamashita TE, et al. Persistent GB virus C infection and survival in HIV-infected men. N Engl J Med 2004; 350:981.
  25. Weintrob AC, Hamilton JD, Hahn C, et al. Active or prior GB virus C infection does not protect against vertical transmission of HIV in coinfected women from Tanzania. Clin Infect Dis 2004; 38:e46.
  26. Soriano-Sarabia N, Abad MA, Vallejo A, et al. Influence of hepatitis C and hepatitis G virus co-infection on viral and cellular dynamics in patients infected with human immunodeficiency virus following interruption of highly active anti-retroviral therapy. Clin Microbiol Infect 2006; 12:290.
  27. Piroth L, Carrat F, Larrat S, et al. Prevalence and impact of GBV-C, SEN-V and HBV occult infections in HIV-HCV co-infected patients on HCV therapy. J Hepatol 2008; 49:892.
  28. Campos AF, Tengan FM, Silva SA, Levi JE. Influence of hepatitis G virus (GB virus C) on the prognosis of HIV-infected women. Int J STD AIDS 2011; 22:209.